TipRanks
Advertisement
Advertisement

TCRX Stock Latest News

TScan Therapeutics Announces Board and Governance Changes
Company AnnouncementsTScan Therapeutics Announces Board and Governance Changes
6d ago
8K
TCRX
TScan Therapeutics Announces Executive Departures Amid Reorganization
PremiumCompany Announcements
TScan Therapeutics Announces Executive Departures Amid Reorganization
22d ago
8K
TCRX
TScan Therapeutics Launches Executive Retention Incentive Program
PremiumCompany Announcements
TScan Therapeutics Launches Executive Retention Incentive Program
1M ago
8K
TCRX
TScan Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
PremiumThe Fly
TScan Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
1M ago
TCRX
TScan downgraded to Market Perform from Outperform at LifeSci Capital
PremiumThe Fly
TScan downgraded to Market Perform from Outperform at LifeSci Capital
2M ago
TCRX
Needham downgrades TScan Therapeutics as company reprioritizes
PremiumThe FlyNeedham downgrades TScan Therapeutics as company reprioritizes
2M ago
TCRX
TScan Therapeutics downgraded to Hold from Buy at Needham
Premium
The Fly
TScan Therapeutics downgraded to Hold from Buy at Needham
2M ago
TCRX
TScan Therapeutics downgraded to Neutral from Outperform at Wedbush
Premium
The Fly
TScan Therapeutics downgraded to Neutral from Outperform at Wedbush
2M ago
TCRX
TScan Therapeutics Restructures to Focus on Solid Tumors
PremiumCompany Announcements
TScan Therapeutics Restructures to Focus on Solid Tumors
2M ago
8K
TCRX
TScan Therapeutics to strategically reorganize, reduce workforce by 75%
PremiumThe Fly
TScan Therapeutics to strategically reorganize, reduce workforce by 75%
2M ago
TCRX
TScan Therapeutics Faces Loss of Key Amgen Partnership
PremiumCompany Announcements
TScan Therapeutics Faces Loss of Key Amgen Partnership
2M ago
8K
TCRX
TScan Therapeutics reports Q2 EPS (23c), consensus (20c)
PremiumThe Fly
TScan Therapeutics reports Q2 EPS (23c), consensus (20c)
2M ago
TCRX
Sam Slutsky Maintains Buy Rating and $6 Price Target on ALLOHA-2 Progress and Cohort C Data De-Risking TSC-101 Program
PremiumRatingsSam Slutsky Maintains Buy Rating and $6 Price Target on ALLOHA-2 Progress and Cohort C Data De-Risking TSC-101 Program
3M ago
TCRX
TScan Therapeutics doses first patient in ALLOHA-2 trial
Premium
The Fly
TScan Therapeutics doses first patient in ALLOHA-2 trial
3M ago
TCRX
TScan’s TSC-101 Trial: A New Cell Therapy Bet in Transplant Oncology
Premium
Company Announcements
TScan’s TSC-101 Trial: A New Cell Therapy Bet in Transplant Oncology
3M ago
TCRX
TScan Therapeutics: Early ALLOHA Phase 1 Efficacy and Safety Reinforce Late-Stage Plans; Buy Rating and $6 Price Target Maintained
PremiumRatings
TScan Therapeutics: Early ALLOHA Phase 1 Efficacy and Safety Reinforce Late-Stage Plans; Buy Rating and $6 Price Target Maintained
4M ago
TCRX
TScan Therapeutics: ALLOHA Data, Streamlined Manufacturing Bolster Buy Rating with $7 Price Target Maintained
PremiumRatings
TScan Therapeutics: ALLOHA Data, Streamlined Manufacturing Bolster Buy Rating with $7 Price Target Maintained
4M ago
TCRX
TScan Therapeutics Advances TSC-101 Toward Pivotal Trial
PremiumCompany Announcements
TScan Therapeutics Advances TSC-101 Toward Pivotal Trial
4M ago
8K
TCRX
TScan Therapeutics presents data from Cohort C of ALLOHA trial
PremiumThe Fly
TScan Therapeutics presents data from Cohort C of ALLOHA trial
4M ago
TCRX
TScan Therapeutics, Cellares enter agreement to evaluate TCS-101 manufacturing
PremiumThe FlyTScan Therapeutics, Cellares enter agreement to evaluate TCS-101 manufacturing
5M ago
TCRX
TScan Therapeutics Expands Authorized Shares After Stockholder Vote
Premium
Company Announcements
TScan Therapeutics Expands Authorized Shares After Stockholder Vote
5M ago
8K
TCRX
Buy Rating Reiterated on TSC-101 Ahead of Key ALLOHA Readouts and Pipeline Expansion; $6 Price Target Maintained
Premium
Ratings
Buy Rating Reiterated on TSC-101 Ahead of Key ALLOHA Readouts and Pipeline Expansion; $6 Price Target Maintained
6M ago
TCRX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >